BioSpace News Archive

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies (“CGT”) and broader biopharma markets, today announced the Company’s first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024.

The Board of Directors of BD, a leading global medical technology company, announced it has declared a quarterly dividend of $0.95 per common share, payable on June 28, 2024 to holders of record on June 10, 2024.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes.

Cytek Biosciences, Inc., a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide.

Jacobio Pharma announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online.

Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent unmet needs present for patients grappling with these rare conditions.

Galapagos NV announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings held on 30 April 2024 were approved.

Ultragenyx Pharmaceutical Inc. released its 2023 Corporate Responsibility Report, which showcases the company’s efforts to transform the lives of individuals and families impacted by rare and ultrarare diseases, empower its employees, and make a meaningful impact on the communities it partners with.